The healthcare community is buzzing about the new drug, a twin-action therapy showing impressive results in clinical trials . This new compound, a incretin receptor alongside a glucose-dependent insulinotropic compound, appears to effectively lower body size and improve metabolic markers. Researchers are suggesting that it has the potential to offe